Connective tissue components of the normal and fibrotic human liver. II. Clinical aspects.
In this second part, clinical aspects of connective tissue metabolism in the liver will be described and two main aspects considered. The first is the possibility to monitor the activity of fibrosis by the use of metabolites and enzymes of connective tissue metabolism. In recent studies the qualification for this purpose of enzymes such as procollagen prolyl hydroxylase and lysosomal N-Acetyl-beta-glucosaminidase and the N-terminal peptide of procollagen type III has been tested. The serum activities or concentrations of these substances in patients with chronic active liver diseases increase in due relation to the histologically estimated activity of liver fibrosis. The second aspect deals with therapeutic approaches to fibrosis in the liver by using connective tissue specific agents. So far none of the antifibrotic substances such as proline analogues, colchicine, lathyrogens and penicillamine has been used in longer-term antifibrotic treatment.
D000118:Acetylglucosaminidase / Q000378:metabolism; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D003094:Collagen / Q000096:biosynthesis; D003238:Connective Tissue / Q000378:metabolism*; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D008107:Liver Diseases / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D008111:Liver Function Tests; D011347:Procollagen / Q000096:biosynthesis
D000933:Antifibrinolytic Agents; D007527:Isoenzymes; D011347:Procollagen; D003094:Collagen; D000118:Acetylglucosaminidase